Biotech Startups

DeuterOncology is a clinical-stage biotech developing DO-2, a deuterated, brain-penetrant MET kinase and RAS pathway inhibitor for cancer patients, currently in a phase 1 clinical study. The molecule was in-licensed from OCTIMET Oncology and originally from Janssen Pharmaceutica.

1 investor

Dexcom develops continuous glucose monitoring (CGM) systems and glucose biosensors, including the Dexcom G7 and the over-the-counter Stelo biosensor, that send real-time glucose readings to a phone or receiver. Its products serve people managing diabetes as well as consumers tracking glucose for general health, diet, and exercise.

1 investor

ModalityDx develops quantitative point-of-care diagnostic tests using molecular biomarkers and data science to detect and assess treatment response for diseases including diabetes, maternal health conditions, and autoimmune disorders. The company also supports pharmaceutical firms in drug development and therapeutic efficacy assessment.

1 investor

Diaceutics operates DXRX, a diagnostic commercialization platform that integrates real-world lab, genomic, clinical, claims, and social-determinants data to help pharma and biotech companies commercialize precision-medicine therapies. Its tools identify testing behaviors and engage physicians to close the gap between diagnostic testing and treatment adoption.

1 investor

Diadem Bio develops therapeutic treatments designed to be safe, powerful, versatile and cost-effective for patients with unmet medical needs, with a focus on potential cancer cures and other difficult diseases.

1 investor

Diadem is a diagnostics company developing AlzoSure, a plasma/blood-based test that uses a proprietary antibody targeting a specific conformation of the p53 protein to predict and diagnose Alzheimer's disease. The test aims to provide early, non-invasive diagnosis and to support patient recruitment for Alzheimer's drug development clinical trials.

1 investor

Hologic Diagenode provides epigenomics profiling services and sample preparation products for next-generation sequencing, proteomics, and epigenetics research. It serves biomarker discovery and validation through epigenomics and bioinformatics for research applications.

1 investor

Dialybrid develops vascular grafts for hemodialysis using Silkothane®, a hybrid material combining silk fibroin and polyurethane, targeting nephrologists and dialysis centers. The company focuses on advanced biomedical devices in the tissue engineering and regenerative medicine sector.

1 investor

Diamante develops plant-based compounds for therapeutic and diagnostic systems targeting autoimmune diseases. The company applies molecular farming techniques to produce biopharmaceuticals and aims to advance treatments from research to clinical applications.

1 investor

Diamidex develops microbiological analysis solutions for water safety, including equipment, software, and reagents designed to detect and count targeted microorganisms with improved speed and accuracy for laboratory use.

1 investor

Dianthus Therapeutics develops antibody-based therapies for patients with severe autoimmune diseases, including its lead complement C1s inhibitor claseprubart (DNTH103) and a bifunctional inhibitor DNTH212 designed for self-administered subcutaneous injection. The company operates in the biotech and drug development sector.

1 investor

Diasome develops metabolic therapies using its HDV platform to enable targeted drug delivery for treating diabetes, obesity, and metabolic diseases. The company focuses on translating therapeutic insights to restore metabolic function using endogenous mechanisms.

1 investor

Diatech Pharmacogenetics provides molecular testing and genetic analysis to enable precision medicine by matching patients with appropriate therapies based on their individual genetic profiles. The company serves healthcare providers and patients seeking personalized treatment options informed by pharmacogenomic data.

1 investor

DIATER develops diagnostic tools and therapeutic treatments for allergy patients using molecular immunotherapy techniques. The company manufactures personalized therapies for complex allergies and operates across Spain, Portugal, and Germany.

1 investor

Diesse develops and manufactures in-vitro diagnostic instruments and reagents for clinical laboratories, including automated ESR (erythrocyte sedimentation rate) analyzers, automated and manual immunoassay systems, and rapid diagnostic tests. Its product lines include VES-MATIC, CHORUS, AUTO-DAT, Enzywell, and iRapid.

1 investor

Differential Bio offers a virtual scale-up platform for bioprocess optimization, using robotic lab automation to gather microliter-scale fermentation data and AI models to simulate and optimize microbial growth, yield, and cost. It serves biotech and industrial fermentation R&D teams looking to derisk and accelerate strain and process development before large-scale production.

1 investor

1 investor

Digestiva develops proprietary protease enzymes that break down proteins to produce more bioaccessible and smaller peptides, increase free amino acid availability, and improve protein yield from co-products and waste streams. Its technology targets applications in health, nutrition, and food processing.

1 investor

Digital Biology (Digit Bio) develops precision biologics and combination therapies for solid tumors, using its M×P (Molecules × Phenotypes) Platform that combines high-resolution imaging, next-generation sequencing, computation, and AI to map the spatial molecular organization of tumor tissues. The company applies this measurement technology to discover spatially synergistic tumor antigen targets for immunotherapies and partners with pharmaceutical companies and foundations in precision oncology.

1 investor

Dimension Bio is a biotechnology company developing regenerative therapeutics using its BioNidum platform, which combines materials science, 3D printing, and digital manufacturing to produce implantable and injectable biosynthetic scaffolds that promote tissue healing. Its products target clinical markets such as sports medicine, orthopedics, plastic and reconstructive surgery, aesthetics, dental, and neuro/spine, as well as cell delivery applications for conditions like liver failure and Type 1 diabetes.

1 investor

A biotech company using AI and dynamic blood biomarkers to develop precision therapeutics for immunology.

1 investor

Diploid Genomics uses phased diploid genome sequencing combined with multimodal clinical data and AI to detect disease earlier and guide personalized care. The company integrates genomic, imaging, and clinical data into a precision health platform designed for healthcare systems, specialty clinics, and biopharma partners.

1 investor

Diptera.ai uses computer vision and insect biology to control pest populations without pesticides, starting with mosquitoes. The company has demonstrated field-tested effectiveness in reducing mosquito numbers in Israel and plans expansion to African regions.

1 investor

DiscGenics develops an allogeneic, injectable disc progenitor cell therapy (IDCT/rebonuputemcel) for painful lumbar degenerative disc disease, currently advancing toward a Phase III clinical program. The company works in regenerative spine medicine and cell therapy, and collaborates on tissue-engineered intervertebral disc research.

1 investor